Loading…
Palvella Therapeutics, Inc. is projected to rise to $155.55 by 2027, a +34% move from its current price of $116.26. PVLA is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $112.18 | $116.33 | $120.63 | +0.06% |
| May 30 | $110.57 | $116.39 | $122.53 | +0.12% |
| May 31 | $109.36 | $116.46 | $124.02 | +0.17% |
| Jun 1 | $108.36 | $116.53 | $125.31 | +0.23% |
| Jun 2 | $107.50 | $116.60 | $126.46 | +0.29% |
| Jun 3 | $106.73 | $116.66 | $127.52 | +0.35% |
| Jun 4 | $106.03 | $116.73 | $128.50 | +0.40% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $106.03 | $116.73 | $128.50 | +0.40% |
| Week 2 | $102.31 | $117.20 | $134.26 | +0.81% |
| Week 3 | $99.63 | $117.68 | $138.99 | +1.22% |
| Week 4 | $97.49 | $118.15 | $143.19 | +1.63% |
| Week 5 | $95.69 | $118.63 | $147.07 | +2.04% |
| Week 6 | $94.13 | $119.11 | $150.72 | +2.45% |
| Week 7 | $92.74 | $119.59 | $154.21 | +2.86% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients with serious and rare genetic skin diseases. Its lead product candidate is QTORIN rapamycin, a novel, 3.9% anhydrous topical gel that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations.
It also develops QTORIN rapamycin for the treatment of angiokeratomas and other mTOR-driven skin diseases; and QTORIN pitavastatin for the treatment of disseminated superficial actinic porokeratosis. The company is based in Wayne, Pennsylvania.
PVLA trades at $113.99 per share and has a market cap of $1.63B. It ranks 2157.
The forecast shows an evolving price path, with a 2026 average price of $113.99 and neutral sentiment (ROI 0). From 2027 onward, the averages rise to $152.20 in 2027, $179.31 in 2028, and $211.17 in 2030, with increasing ROI and a bullish tilt through the mid-2030s. In the long run, the forecast projects substantial upside, including a 2040 average of $846.05 and a 2050 average of $1,452.64, with corresponding ROI figures of 642.2% and 1174.4% respectively.
A major floor 34.3% below — a decisive break under it would weaken the trend.
The nearest floor, 9.6% below — buyers have tended to step in here.
The nearest ceiling, 12.4% above — a clean break opens room to run.
A major ceiling 27.6% above — clearing it would confirm fresh momentum.
Key PVLA support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of PVLA market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $115.85 | Buy | $115.66 | Buy |
| MA 10 | $114.73 | Buy | $116.23 | Buy |
| MA 20 | $119.73 | Sell | $118.49 | Sell |
| MA 50 | $121.53 | Sell | $118.97 | Sell |
| MA 100 | $111.59 | Buy | $111.59 | Buy |
| MA 200 | $92.81 | Buy | $94.14 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 46.82 | Neutral |
| Stoch RSI (14) | 72.62 | Neutral |
| CCI (20) | -40.35 | Neutral |
| Williams %R (14) | -45.95 | Info |
| MACD (12,26,9) | -0.33 | Sell |
| ROC (12) | -4.15 | Sell |
| Bollinger %B (20,2) | 0.37 | Neutral |
| Stochastic %K (14) | 54.05 | Neutral |
| TRIX (15) | -0.28 | Sell |
| Awesome (5,34) | -7.36 | Sell |
| Ultimate (7,14,28) | 48.68 | Neutral |
| Momentum (10) | -9.53 | Sell |
| Aroon Osc (25) | -76.00 | Sell |
| Hull MA (9) | 117.24 | Sell |
| ADX (14) | 10.67 | Neutral |
| ATR (14) | 3.79 | Info |
The 30-day technical picture shows bullish sentiment. RSI14 is 40, and the asset trades with the 50-day moving average at $121.81 and the 200-day moving average at $92.05. Price is currently around $113.99, sitting below the SMA50 but above the SMA200.
Support is at $105.05 and resistance at $130.65. The 30-day price range runs from $88.70 to $146.49, and annualized volatility is 70%.
This setup suggests a range-bound near-term posture with an upside tilt if momentum strengthens above the $130.65 resistance, while a break below $105.05 could raise downside risk. Investors may monitor how price action interacts with the 50-day and 200-day averages as well as the 30-day range for potential breakouts or pullbacks.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $76.43 | $116.26 | $164.17 | 0% | Neutral | |
| $119.42 | $155.55 | $216.80 | +34% | Bullish | |
| $136.73 | $184.91 | $269.65 | +59% | Bullish | |
| $133.25 | $185.99 | $281.05 | +60% | Bullish | |
| $153.66 | $220.65 | $343.52 | +90% | Bullish | |
| $197.30 | $290.82 | $464.69 | +150% | Bullish | |
| $243.92 | $368.47 | $602.61 | +217% | Bullish | |
| $271.70 | $420.08 | $701.61 | +261% | Bullish | |
| $277.69 | $439.00 | $747.48 | +278% | Bullish | |
| $298.23 | $481.68 | $834.94 | +314% | Bullish | |
| $507.89 | $905.99 | $1,691.68 | +679% | Bullish | |
| $745.49 | $1,591.67 | $3,307.53 | +12.7x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $76.43 | $116.26 | $136.86 | +0.00% |
| June 2026 | $99.06 | $117.18 | $142.52 | +0.79% |
| July 2026 | $102.43 | $122.54 | $151.69 | +4.57% |
| August 2026 | $101.93 | $123.02 | $154.36 | +0.40% |
| September 2026 | $98.08 | $119.25 | $151.29 | -3.06% |
| October 2026 | $99.03 | $121.22 | $155.32 | +1.65% |
| November 2026 | $102.40 | $126.10 | $162.96 | +4.02% |
| December 2026 | $101.75 | $126.00 | $164.17 | -0.07% |
Click any year to see its month-by-month PVLA forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, PVLA is projected to trade between $76.43 and $164.17, averaging $116.26 — a potential gain of 0% from today's $116.26. Price action looks broadly range-bound.
Palvella Therapeutics, Inc.'s 2027 outlook centres on $155.55, within a $119.42 to $216.80 range. That is up +34% on the projected 2026 average. That marks a +34% change versus current levels. Buyers look set to stay in control over this stretch.
By 2028, PVLA could reach as high as $269.65, with a base case around $184.91 and support toward $136.73 — roughly +59% from $116.26. Momentum favours further upside here.
Expect PVLA to range from $133.25 to $281.05 through 2029. The $185.99 average target implies a +60% move from current prices. That is up +1% on the projected 2028 average. Buyers look set to stay in control over this stretch.
The PVLA price prediction for 2030 points to an average of $220.65 (low $153.66, high $343.52) — a potential gain of +90% on today's $116.26. Momentum favours further upside here.
In 2031, PVLA is projected to trade between $197.30 and $464.69, averaging $290.82 — a potential gain of +150% from today's $116.26. That is up +32% on the projected 2030 average. Buyers look set to stay in control over this stretch.
Palvella Therapeutics, Inc.'s 2032 outlook centres on $368.47, within a $243.92 to $602.61 range. That is up +27% on the projected 2031 average. That marks a +217% change versus current levels. Momentum favours further upside here.
By 2033, PVLA could reach as high as $701.61, with a base case around $420.08 and support toward $271.70 — roughly +261% from $116.26. Buyers look set to stay in control over this stretch.
Expect PVLA to range from $277.69 to $747.48 through 2034. The $439.00 average target implies a +278% move from current prices. That is up +5% on the projected 2033 average. Momentum favours further upside here.
The PVLA price prediction for 2035 points to an average of $481.68 (low $298.23, high $834.94) — a potential gain of +314% on today's $116.26. Buyers look set to stay in control over this stretch.
In 2040, PVLA is projected to trade between $507.89 and $1,691.68, averaging $905.99 — a potential gain of +679% from today's $116.26. That is up +88% on the projected 2035 average. Momentum favours further upside here.
Palvella Therapeutics, Inc.'s 2050 outlook centres on $1,591.67, within a $745.49 to $3,307.53 range. That is up +76% on the projected 2040 average. That marks a +12.7x change versus current levels. Buyers look set to stay in control over this stretch.
Investing $1,000 in PVLA today (≈ 8.601411 PVLA) could be worth
$13,690.63
+$12,690.63 (+1269%) by 2050 · US Dollar
Based on the average projected PVLA price of $1,591.67 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in PVLAwould be worth at today's price.
$1,000 invested in PVLA on May 27, 2025 (≈ 43.591978 PVLA) would be worth
$5,068
+$4,068 (+406.8%) today · 5.07× · US Dollar
Based on a PVLA entry price of $22.94 vs. today's $116.26.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $115.5 | $1,006.58 | +0.7% |
| 1 month ago | $128.64 | $903.76 | -9.6% |
| 3 months ago | $148.34 | $783.74 | -21.6% |
| 6 months ago | $102.79 | $1,131.04 | +13.1% |
| 1 year ago | $22.94 | $5,068 | +406.8% |
| All time (5.0y) ago | $268.8 | $432.51 | -56.7% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our PVLA forecast.
Our base-case forecast reaches $230.00 around 2031.
Implied market cap at $230.00: $3.3B
The multi-year forecast outlines a path of sustained upside, with the average price rising from $113.99 in 2026 to $211.17 in 2030 (ROI 85.3%), then to $846.05 in 2040 (ROI 642.2%) and ultimately to $1,452.64 in 2050 (ROI 1174.4%). The 2027 average is $152.20 (ROI 33.5%), the 2028 average is $179.31 (ROI 57.3%), and the 2029 average is $175.62 (ROI 54.1%), followed by continued bullish momentum through 2031–2035 with meaningful upside. The long-range outlook remains bullish through 2050, with higher average prices and substantial ROI projected, though these are estimates and not guarantees.
These figures provide a framework for potential value progression over time, subject to the typical uncertainties that accompany long-horizon forecasts.
Tap a question to reveal the answer.
The forecast shows a 2030 average price of $211.17 with a max of $332.89 and a min of $145.24, and ROI 85.3%.
The forecast indicates bullish sentiment in 2027, 2028, 2029, 2030 and beyond, with rising average prices and positive ROI in those years (for example, 2027 avg $152.20 with ROI 33.5%, 2028 avg $179.31 with ROI 57.3%, 2029 avg $175.62 with ROI 54.1%). However, 2026 shows neutral sentiment and ROI 0, and these figures are estimates, not guarantees.
Yes. The 2050 forecast lists an average of $1,452.64 with ROI 1174.4%, indicating potential above $1,000 in the long run.
Current price is $113.99 and market cap is $1.63B.
The 2031 forecast shows an average price of $278.58 with a min of $186.38, a max of $451.13, and ROI 144.4%, with bullish sentiment.
Palvella Therapeutics, Inc. Community Discussion
0Share your Palvella Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.